

(PB4035) LETERMIVIR FOR CYTOMEGALOVIRUS PREVENTION IN RELAPSED/REFRACTORY ACUTE LEUKEMIA AND LYMPHOMA RECEIVING SEQUENTIAL CD7 CAR-T CELL THERAPY BRIDGING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

Topic: 23. Stem cell transplantation - Clinical

Linwei Shi^{*1}, Aiming Pang¹

¹*Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Hematology & Blood Diseases Hospital, Tianjin, China;*

Background

To evaluate the real-world safety and efficiency of letermovir in preventing cytomegalovirus infection in patients undergoing sequential CD7 CAR-T cell therapy bridging allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute leukemia and lymphoma.

Methods

This single-center, retrospective, observational study enrolled patients with relapsed/refractory acute leukemia and lymphoma who received sequential CD7 CAR-T cell therapy bridging allo-HSCT at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences from 1st June, 2024- 1st May, 2025. All enrolled patients were scheduled to receive letermovir for CMV prophylaxis. Prophylaxis was initiated within one week after transplantation and continued until day 100 post-allo-HSCT. The primary endpoint was the breakthrough CMV infection rate.

Results

A total of 9 patients were enrolled, including 5 with T-lymphoblastic leukemia/lymphoma, 3 with T-cell acute lymphoblastic leukemia (T-ALL), and 1 with mixed-phenotype acute leukemia. Eight patients received autologous CAR-T cell therapy, while 1 received allogeneic CAR-T cells. The median time from diagnosis to CAR-T cell infusion was 119 days (83-285 days), and the median time from CAR-T cell infusion to hematopoietic stem and progenitor cell (HSPC) infusion was 57 days (41-74 days). The median follow-up time from CAR-T cell infusion was 5.6 months (2.5-11.9 months), and the median overall survival (OS) for all patients was 10.5 months (6.6-16.6 months).

All 9 patients who received CD7 CAR-T cell therapy bridging allo-HSCT started letermovir prophylaxis within one week after transplantation initiation (**Figure 1**). The median duration of letermovir prophylaxis was 100 days (19-100 days). During prophylaxis, 3 patients (33.3%) required intensive care unit admission due to severe infections. One patient (11.1%) experienced a breakthrough CMV infection on day 14 post-transplantation, with an initial CMV DNA load of 914 copies/mL; the infection resolved after 2 days of adjunctive ganciclovir therapy, with subsequent CMV DNA conversion to negative. Five patients completed letermovir prophylaxis until day 100 post-transplant, and none of these patients developed CMV infection from drug discontinuation until the end of follow-up. However, 3 patients (33.3%) developed Epstein-Barr virus (EBV) infection during letermovir prophylaxis, including 1 case of refractory EBV infection. The median time to EBV viremia onset was 60 days post-transplantation, with a mean duration of 27.0 days. Four patients died due to infections post-transplantation; notably, 3 of these 4 patients had EBV viremia, with 1 death directly attributed to EBV infection and the others to severe infections. Letermovir prophylaxis demonstrated a favorable safety profile, with no serious adverse events related to the drug observed.


Copyright Information: (Online) ISSN: 2572-9241

©2026 The Author(s). HemaSphere is published by John Wiley & Sons Ltd on behalf of European Hematology Association. This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND), which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. **Abstract Book Citations:** Authors, Title, HemaSphere, 2026;10;(S1):pages. The abstract book DOIs can be found on the "Author Information" page.

Disclaimer: Articles published in the journal HemaSphere exclusively reflect the opinions of the authors. The authors are responsible for all content in their abstracts including accuracy of the facts, statements, citing resources, etc.

Summary/Conclusion

In a real-world setting, letermovir demonstrated significant efficacy in preventing CMV infection in patients with acute leukemia and lymphoma undergoing sequential CD7 CAR-T cell therapy bridging allo-HSCT. The high risk of CMV reactivation post-CAR-T therapy has been confirmed in multiple studies. The CMV infection rate observed in this study is significantly lower than previously reported rates for CD7 CAR-T bridging transplantation. Further large-scale cohorts will hold greater promise to verify letermovir for CMV prophylaxis in high-risk populations undergoing CD7 CAR-T bridging allo-HSCT.



All 9 patients who received CD7 CAR-T cell therapy bridging allo HSCT started letermovir prophylaxis within one week after transplantation initiation